Profile data is unavailable for this security.
About the company
Sartorius Stedim Biotech SA is a France-based international provider of laboratory and process technologies and equipment. The Company covers the segments of biotechnology and mechatronics. Sartorius provides services which help customers to implement complex and quality-critical processes in biopharmaceutical production and laboratory environments in a time- and cost-efficient way. The Company’s customers are from the biotech, pharma and food industries, as well as from public research institutes and laboratories. Sartorius operates its own production facilities in Europe, Asia and America, and also has sales offices and local representatives in more than 110 countries. The Company operates through its subsidiaries, including Sartorius Stedim Austria GmbH, Sartorius Stedim Plastics GmbH, BioOutsource Ltd and Wave Biotech AG, among others.
- Revenue in EUR (TTM)2.75bn
- Net income in EUR169.20m
- Incorporated1978
- Employees10.38k
- LocationSartorius Stedim Biotech SABp 1051, Aubagne CedexAUBAGNE 13781FranceFRA
- Phone+33 442845600
- Fax+33 442845619
- Websitehttps://www.sartorius.com/en/company/about-sartorius-stedim-biotech-sa
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Smith & Nephew plc | 5.39bn | 291.25m | 10.31bn | 18.00k | 35.35 | 2.07 | 11.20 | 1.91 | 0.2775 | 0.2775 | 5.13 | 4.73 | 0.5535 | 0.7128 | 4.30 | 242,940.50 | 2.99 | 4.10 | 3.62 | 4.99 | 69.04 | 71.27 | 5.41 | 8.02 | 1.11 | 5.48 | 0.4125 | 79.59 | 6.40 | 2.50 | 17.94 | -16.88 | 4.24 | 1.85 |
| BioMerieux SA | 3.81bn | 411.30m | 11.42bn | 14.65k | 27.87 | 2.94 | 16.19 | 3.00 | 3.46 | 3.46 | 32.04 | 32.80 | 0.7356 | 1.82 | 5.63 | 259,811.60 | 7.71 | 9.30 | 9.57 | 12.31 | 55.72 | 56.51 | 10.48 | 12.38 | 1.20 | 236.14 | 0.1258 | 17.76 | 2.39 | 8.70 | -20.95 | 6.87 | 8.36 | 19.42 |
| Sartorius AG | 3.32bn | 83.20m | 13.93bn | 13.76k | 138.13 | 4.34 | 26.76 | 4.19 | 1.22 | 1.22 | 48.66 | 38.73 | 0.3365 | 1.84 | 9.34 | 227,432.60 | 1.37 | 8.21 | 1.73 | 11.83 | 43.95 | 50.93 | 4.06 | 14.15 | 1.13 | 2.41 | 0.545 | 19.59 | -18.66 | 16.74 | -69.74 | 7.74 | 19.14 | 3.66 |
| Sartorius Stedim Biotech SA | 2.75bn | 169.20m | 16.41bn | 10.38k | 94.13 | 4.22 | 35.93 | 5.97 | 1.79 | 1.79 | 29.22 | 39.95 | 0.4145 | 1.75 | 8.84 | 257,644.00 | 2.61 | 11.87 | 3.04 | 15.12 | 41.82 | 50.96 | 6.31 | 17.44 | 1.03 | 2.95 | 0.4266 | 18.73 | -20.53 | 18.02 | -64.65 | 8.28 | 21.82 | 3.90 |
| Straumann Holding AG | 2.66bn | 330.75m | 18.68bn | 11.15k | 56.48 | 8.81 | 38.84 | 7.03 | 1.93 | 1.70 | 15.47 | 12.34 | 0.715 | 1.76 | 4.21 | 222,176.90 | 8.95 | 10.68 | 11.84 | 13.63 | 72.76 | 74.95 | 12.52 | 15.15 | 1.55 | 13.15 | 0.187 | 37.50 | 3.92 | 12.08 | -43.40 | -2.04 | 11.54 | 10.12 |
| Sonova Holding AG | 3.99bn | 608.01m | 19.52bn | 18.55k | 32.23 | 7.91 | 22.19 | 4.89 | 9.43 | 9.43 | 61.94 | 38.43 | 0.6838 | 2.33 | 6.84 | 204,236.70 | 10.54 | 10.87 | 13.40 | 13.88 | 72.42 | 71.97 | 15.42 | 17.77 | 0.823 | 21.70 | 0.419 | 35.21 | -2.98 | 5.59 | -5.84 | 5.77 | 1.75 | 8.20 |
| Koninklijke Philips NV | 18.04bn | -469.00m | 23.53bn | 69.28k | -- | -- | 33.42 | 1.30 | -0.4847 | -0.335 | 19.14 | -- | -- | -- | -- | 258,972.70 | -- | 0.3678 | -- | 0.5013 | 42.18 | 43.84 | -2.59 | 0.6049 | -- | 5.35 | -- | -- | 1.92 | 0.0529 | 71.87 | -- | -5.24 | -- |
| Coloplast A/S | 3.62bn | 677.35m | 24.61bn | 16.25k | 38.61 | 10.97 | 28.94 | 6.79 | 22.61 | 22.61 | 121.01 | 79.62 | 0.5618 | 2.44 | 6.01 | 1,663,692.00 | 10.50 | 16.21 | 14.49 | 22.91 | 67.59 | 67.85 | 18.69 | 21.02 | 0.6637 | 8.49 | 0.5578 | 92.23 | 10.33 | 8.54 | 5.62 | 5.46 | 14.30 | 5.29 |
| Holder | Shares | % Held |
|---|---|---|
| Comgest SAas of 31 Jul 2024 | 1.16m | 1.19% |
| The Vanguard Group, Inc.as of 06 Nov 2024 | 872.88k | 0.90% |
| T. Rowe Price International Ltd.as of 08 Nov 2024 | 777.34k | 0.80% |
| Baillie Gifford & Co.as of 31 Oct 2024 | 723.43k | 0.74% |
| BlackRock Fund Advisorsas of 07 Nov 2024 | 586.32k | 0.60% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 516.34k | 0.53% |
| DNCA Finance SAas of 31 Dec 2023 | 430.00k | 0.44% |
| Invesco Advisers, Inc.as of 07 Nov 2024 | 411.46k | 0.42% |
| Fidelity Management & Research Co. LLCas of 07 Nov 2024 | 382.29k | 0.39% |
| Select Equity Group LPas of 30 Sep 2024 | 371.68k | 0.38% |
